Novartis AG (ADR) (NYSE:NVS)

CAPS Rating: 5 out of 5

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.

Results 1 - 20 of 186 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar oncqueen (69.49) Submitted: 8/30/2014 10:11:55 AM : Outperform Start Price: $92.95 NVS Score: -1.13

New blockbuster drug for heart failure in the works, with a 20% reduction in death vs standard rx, and a decrease in hospitalization. Buying it in the real world next market day. Dividend around 2.7%, too.

Recs

1
Member Avatar bricehobbs (< 20) Submitted: 5/14/2014 1:46:32 PM : Outperform Start Price: $89.48 NVS Score: -3.22

Dividend, M & A activity, and pipeline.

Recs

1
Member Avatar fischdoctor (61.88) Submitted: 10/28/2013 8:22:30 AM : Outperform Start Price: $77.45 NVS Score: +4.25

good solid company.

Recs

1
Member Avatar alexf (< 20) Submitted: 8/29/2013 10:36:41 AM : Outperform Start Price: $70.99 NVS Score: +7.20

Good mix of products. Good management.

Recs

1
Member Avatar wilkeh (40.57) Submitted: 6/6/2013 10:15:14 AM : Outperform Start Price: $69.30 NVS Score: +7.98

diversified healthcare company will become the largest healthcare (pharma) company in the world in terms of revenue

Recs

0
Member Avatar kbelboe2 (38.34) Submitted: 7/13/2012 11:26:25 PM : Outperform Start Price: $52.90 NVS Score: +24.58

Another Euro drug manufacturer that now does generic stuff. Cheap and about to go higher.

Recs

0
Member Avatar pphamelin (73.68) Submitted: 6/26/2012 2:30:36 PM : Outperform Start Price: $51.67 NVS Score: +25.17

lack of patent protection overhyped

Recs

0
Member Avatar allegra (60.34) Submitted: 3/12/2012 2:07:13 PM : Outperform Start Price: $51.20 NVS Score: +31.81

pharmy and generic pipeline, biotech, plus optical

Recs

0
Member Avatar renoryan100 (49.00) Submitted: 2/29/2012 10:43:28 AM : Outperform Start Price: $51.85 NVS Score: +29.82

Dividend Monk

Recs

1
Member Avatar Raufus (41.95) Submitted: 2/26/2012 10:58:52 AM : Outperform Start Price: $52.08 NVS Score: +27.84

Novartis is the world's third largest pharmaceutical company with blockbuster products such as Glivec/Tasigna (cancer) and Gilenya (multiple sclerosis). PE at 9.6 and a net dividend yield of 4.8%. The market will reflect that.

Recs

1
Member Avatar Dan22italy (42.72) Submitted: 12/19/2011 1:00:13 AM : Outperform Start Price: $51.35 NVS Score: +13.85

one of best pharma, good dividend

Recs

0
Member Avatar starbucks4ever (98.71) Submitted: 11/18/2011 2:07:58 AM : Outperform Start Price: $50.42 NVS Score: +17.64

A reasonably safe bet. The management is finished destroying value through acquisitions: the last cash that remained to be squandered has been squandered last year, and during a debt crisis nobody will lend them money for the next purchase. That leaves us with a low PE, and with speculators assuming (mistakenly) that with no more empire building the "E" will finally accrue to them. This illusion will put a floor under the price, especially when the "E" is stable and speculators are desperately looking for stability.

Recs

0
Member Avatar MojoJoe (61.23) Submitted: 9/21/2011 11:34:38 AM : Outperform Start Price: $50.89 NVS Score: +12.40

Excellent company, great dividend analysis.

Recs

0
Member Avatar clayman14 (22.33) Submitted: 9/15/2011 4:30:29 PM : Outperform Start Price: $51.13 NVS Score: +13.61

Swiss Compant + Decent Yield + Pharma

Recs

0
Member Avatar beadnell (94.31) Submitted: 8/4/2011 6:17:09 AM : Outperform Start Price: $53.99 NVS Score: +8.41

It is a good day to buy European stocks (even cheaper than when I bought it.)

Recs

0
Member Avatar Jamanji (75.39) Submitted: 7/8/2011 10:36:44 AM : Outperform Start Price: $56.94 NVS Score: +10.85

Barrons 7-4-11

Recs

0
Member Avatar utri (< 20) Submitted: 7/1/2011 11:44:37 AM : Outperform Start Price: $55.60 NVS Score: +13.87

Has exposure to both patented and generic medicine.
Good balance sheet.
Should move up after Alcon acquisition is complete.

Recs

0
Member Avatar FuriousGreen (96.34) Submitted: 5/2/2011 2:20:51 PM : Outperform Start Price: $54.18 NVS Score: +21.65

Solid in recession, solid outside of recession.

Recs

0
Member Avatar PsychoDr (95.48) Submitted: 4/22/2011 9:29:00 AM : Outperform Start Price: $52.12 NVS Score: +25.20

One part of my health care triple play. Novartis is a pharmaceutical company with a nice dividend, international reach, and generic drug presence. Generics are the wave of the future and any company that can provide lower price medication for an emerging international market community is a strong long term play. Health care will see significant growth going forward, I want in on all aspects of the industry.

Recs

0
Member Avatar jtothes (65.74) Submitted: 4/14/2011 10:29:13 AM : Outperform Start Price: $50.84 NVS Score: +26.70

Undervalued? Maybe, but with some new FDA approvals there should be ample opportunity for growth

Featured Broker Partners


Advertisement